ArticleInfection and immunity2003
Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague.Frontiers in microbiology · 2023Article
- Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016Review
- Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.PloS one · 2014Article
- Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques.Human vaccines & immunotherapeutics · 2014Article
- Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization.Cellular & molecular immunology · 2011Article
- Article
- Protection against pneumonic plague following oral immunization with a non-replicating vaccine.Vaccine · 2010Article
- Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.Vaccine · 2010Article
- Novel and unique diagnostic biomarkers for Bacillus anthracis infection.Applied and environmental microbiology · 2009Article
- Article
- An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.Vaccine · 2009Article
- A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.Infection and immunity · 2008Article
- Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.Infection and immunity · 2007Article
- Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
- Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration.Infection and immunity · 2006Article
- Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.Infection and immunity · 2006Article
- Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis.Infection and immunity · 2006Article
- Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.Infection and immunity · 2006Article
- A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.Vaccine · 2004Article
- Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates.Infection and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three plasmids expressing derivatives of the Yersinia pestis capsular F1 antigen were evaluated for their potential as DNA vaccines. These included plasmids expressing the full-length F1, F1 devoid of its putative signal peptide (deF1), and F1 fused to the signal-bearing E3 polypeptide of Semliki Forest virus (E3/F1). Expression of these derivatives in transfected HEK293 cells revealed that deF1 is expressed in the cytosol, E3/F1 is targeted to the secretory cisternae, and the nonmodified F1 is rapidly eliminated from the cell. Intramuscular vaccination of mice with these plasmids revealed that the vector expressing deF1 was the most effective in eliciting anti-F1 antibodies. This response was not limited to specific mouse strains or to the mode of DNA administration, though gene gun-mediated vaccination was by far more effective than intramuscular needle injection. Vaccination of mice with deF1 DNA conferred protection against subcutaneous infection with the virulent Y. pestis Kimberley53 strain, even at challenge amounts as high as 4,000 50% lethal doses. Antibodies appear to play a major role in mediating this protection, as demonstrated by passive transfer of anti-deF1 DNA antiserum. Taken together, these observations indicate that a tailored genetic vaccine based on a bacterial protein can be used to confer protection against plague in mice without resorting to regimens involving the use of purified proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.